Latham & Watkins advised Owlet in the offering, and DLA Piper advised Titan Partners Group, as underwriter. Owlet, Inc. (NYSE:OWLT), the pioneer of smart infant monitoring,...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Seres Therapeutics, while Mayer Brown represented Société des Produits Nestlé on the deal. Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics...
You must be a Standard 1 Year member to access this content.
Akin advised Vista Credit Partners, and Latham & Watkins advised VideoAmp. VideoAmp announced $150 million in Series G funding led by Vista Credit Partners. The funding...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised YES on the transaction. Yield Engineering Systems (YES) has announced a $55 million IP-backed financing from a fund managed by Aon Advantage...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Owlet in the financing round. Owlet, Inc. (NYSE: OWLT) announced it has consummated a sale of its newly issued Series A convertible...
You must be a Standard 1 Year member to access this content.
Barclays served as financial advisor and Latham & Watkins served as legal advisor to Ouster. BofA Securities, Inc. served as financial advisor and Skadden, Arps, Slate,...
You must be a Standard 1 Year member to access this content.
Latham & Watkins and Dentons represented atai in the transaction. atai Life Sciences (“atai”) announced the closing of a venture debt loan facility of up to...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Ouster, Inc. on the deal. Ouster, Inc., a leading lidar technology developer, executed an up to US$50 million structured debt facility from Hercules...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Innocoll Biotherapeutics in the transaction. Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, has announced the successful...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Arcutis in the transaction. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing novel innovations in immuno-dermatology, has announced that...
You must be a Standard 1 Year member to access this content.
